



Resonance Health Limited

ASX: RHT

Annual General Meeting

20th November 2015



AGM Presentation

- Company Financial Summary
- Products:
 - Year in review and strategy
- New Opportunities
- Overall Summary



Resonance Health Limited

- RHT specialises in the development and delivery of non-invasive quantitative medical imaging software and services
- Market capitalisation ~ AU\$ 12.5 million (approx. 400 million shares on issue)
- Net profit reported of \$463k for 2014/15 financial year
- Cash on hand at 30 September of \$2.8 million



Year in Review




- ✓ 24 new sites established & 14% increase in sales receipts across FerriScan and cardiac T2*
- ✓ 29% increase in sales volumes for routine clinical use in UK market and significant increases in other key markets
- ✓ More clinicians using our services (12% increase)
- ✓ Collaborating with pharma, imaging and patient organisations
- ✓ Invited member of The Liver Forum
 - Facilitate drug development for the treatment of liver disease
 - Academics, pharma, medical device and regulators (FDA)
 - Attended all 3 meetings so far
- ✓ Completed corporate re-branding, new website, improved corporate communications (web-site news-flow, customer newsletter)



Year in Review: FerriScan

- Routine clinical use growing
 - Completed 30,000+ FerriScans since on market
 - Several UK and Canadian customers have completed 1,000+
- Continued use in pharmaceutical trials
- Service operation is a profitable business unit
- Available in 30+ countries



FerriScan: Strategy


- Grow revenue in targeted markets
 - Provide solid income base to grow the Company and develop new products for larger opportunities
 - Increase marketing efforts; anticipate return in next financial year

Strategy

1) Sickle Cell Disease (USA)

- Inherited blood disorder, sickle shaped blood cells
- Occlude small blood vessels: tissue/organ damage
- Blood transfusions lead to iron overload

2) Expand pharma / industry supported programs



FerriScan: Strategy

1) Sickle Cell Disease (USA)

~ 70,000 patients with SCD in USA¹ (~15,000 transfused)
~ 1,000 babies born in USA with SCD each year

- Paediatric hospitals provide comprehensive care for SCD patients
- Introduce FerriScan as part of routine care
- Additional resource to target this market
- Potential to increase FerriScan sales by 20 – 40%



2) Expand pharma/industry supported programs

- Collaborate with pharma and patient advocacy organisations
- Improve access to FerriScan in areas where funding may be an issue (e.g. no reimbursement or in developing countries)




Review & Strategy: HepaFat-Scan

- Winner of 2014 WA **Innovator of the Year** award
- Studies to **generate data and publications** that will enhance acceptance and uptake in clinical community
 - 3 active studies and 5+ further opportunities

Strategy

- 1) Liver surgery - Immediate opportunity
 - Liver surgery USA: ~ 30k - 40k cases¹
- 2) Paediatric hospitals
- 3) NAFLD and NASH long term opportunity as drugs come onto market
- 4) Pharma clinical trial use for monitoring efficacy



Review & Strategy: Fibrosis Measurement

- **Two Prototypes Developed:**
 - Screening test to detect whether liver is normal or has fibrosis
 - Test to distinguish between low and high fibrosis in a Hep C cohort¹

Strategy


- 1) Prototypes are pre-market
 - Pharma clinical trial use for monitoring efficacy
 - Actively collecting additional data for validation
- 2) Investigating the opportunity to apply for CE mark
- 3) Continue R&D to increase competitive advantage
 - Collaborate with CSIRO
- 4) Combine with HepaFat-Scan measurement



HepaFat-Scan & Fibrosis Measurement

Potential Market (USA)

Total population:	~320	million
30% fatty liver disease ¹ :	~96	million
3-5% develop NASH:	~3-5	million (assume 4 million)



4 million patients potentially in need of non-invasive liver fat and fibrosis measurement


- Drugs currently in development will drive the need for this test
- Patients will require monitoring
- Multiple pharma competing in this space (Intercept, Shire, Galmed, Gilead, Immuron, etc...)



New R&D

Develop and Grow Company:

- 1) Add value to existing products
- 2) Diversify: add new products to portfolio



Add Value:

- Combine FerriScan with a fibrosis measurement
- Bone marrow iron assessment

Diversify:

- Evaluating opportunities for non-invasive MRI based brain measurements (e.g. Alzheimer's; ~30 million people worldwide¹)
- Identify unmet needs for non-invasive biomarkers
- Collaborate with R&D partners to commercialise new technology



Summary & Overall Strategy

- Profitable FY 14/15, cash on hand
- Focus on growth and development of Company
- **FerriScan:** Niche product
 - Potential to grow (SCD & new markets)
 - Revenue used to fund R&D on other products
- **HepaFat-Scan**
 - Short term: liver surgery
 - Long term pharma companies and NAFLD
- **Fibrosis Measurement**
 - Explore regulatory pathway for prototype
 - Continue R&D and collaborate with pharma
- **Other R&D**
 - **Value add** to existing products and **diversify**

Increased value:

Combinations of the three tests to provide a comprehensive overview of liver health



End of Presentation

